Ismail Kasujee

523 total citations
30 papers, 336 citations indexed

About

Ismail Kasujee is a scholar working on Dermatology, Physiology and Epidemiology. According to data from OpenAlex, Ismail Kasujee has authored 30 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Dermatology, 9 papers in Physiology and 8 papers in Epidemiology. Recurrent topics in Ismail Kasujee's work include Asthma and respiratory diseases (9 papers), Allergic Rhinitis and Sensitization (8 papers) and Dermatology and Skin Diseases (7 papers). Ismail Kasujee is often cited by papers focused on Asthma and respiratory diseases (9 papers), Allergic Rhinitis and Sensitization (8 papers) and Dermatology and Skin Diseases (7 papers). Ismail Kasujee collaborates with scholars based in Spain, Switzerland and United Kingdom. Ismail Kasujee's co-authors include Enrico Maggi, Andrea Matucci, Alessandra Vultaggio, Sapna Srivastava, Adel Mansur, Julie Sullivan, Stefano Piaserico, Deepak Balak, Gabriella Fabbrocini and Claus Kroegel and has published in prestigious journals such as SHILAP Revista de lepidopterología, European Respiratory Journal and Thorax.

In The Last Decade

Ismail Kasujee

21 papers receiving 330 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ismail Kasujee Spain	8	207	122	96	78	48	30	336
Angela Duff Hogan United States	7	115 0.6×	49 0.4×	70 0.7×	89 1.1×	29 0.6×	22	276
Matthias Urban Austria	11	147 0.7×	171 1.4×	36 0.4×	26 0.3×	40 0.8×	28	314
Sandhya Khurana United States	9	321 1.6×	259 2.1×	110 1.1×	74 0.9×	9 0.2×	29	442
Zenon Siergiejko Poland	9	392 1.9×	363 3.0×	43 0.4×	157 2.0×	25 0.5×	46	503
Nikolina Icitovic United States	8	393 1.9×	275 2.3×	131 1.4×	85 1.1×	20 0.4×	12	506
Mariana Fernandes United Kingdom	12	548 2.6×	437 3.6×	129 1.3×	141 1.8×	12 0.3×	59	702
Sarah Diver United Kingdom	9	437 2.1×	322 2.6×	138 1.4×	111 1.4×	46 1.0×	26	587
Reinier Wener Belgium	6	588 2.8×	488 4.0×	104 1.1×	98 1.3×	11 0.2×	17	690
Lyda Cuervo‐Pardo United States	7	47 0.2×	46 0.4×	46 0.5×	29 0.4×	12 0.3×	34	227
Bina Patel United States	6	92 0.4×	28 0.2×	257 2.7×	75 1.0×	10 0.2×	10	471

Countries citing papers authored by Ismail Kasujee

Since Specialization

Citations

This map shows the geographic impact of Ismail Kasujee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ismail Kasujee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ismail Kasujee more than expected).

Fields of papers citing papers by Ismail Kasujee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ismail Kasujee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ismail Kasujee. The network helps show where Ismail Kasujee may publish in the future.

Co-authorship network of co-authors of Ismail Kasujee

This figure shows the co-authorship network connecting the top 25 collaborators of Ismail Kasujee. A scholar is included among the top collaborators of Ismail Kasujee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ismail Kasujee. Ismail Kasujee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Domenech, Arnau, et al.. (2025). Systematic Review of the Use of the WHO-5 Well-Being Index Across Different Disease Areas. Advances in Therapy. 42(8). 3657–3677. 2 indexed citations

Jardin, Kristian Gaarn du, et al.. (2025). Predictors of Flares and Disease Severity in Patients With Atopic Dermatitis Using Machine Learning. JAMA Dermatology. 161(9). 950–950.

Graber, Emmy, Hilary Baldwin, & Ismail Kasujee. (2024). 54052 Safety of sarecycline for treatment of acne vulgaris (AV): Real-world results from the PROSES study. Journal of the American Academy of Dermatology. 91(3). AB308–AB308.

Jardin, Kristian Gaarn du, et al.. (2024). Characterization of patients with atopic dermatitis based on flare patterns and severity of disease: A Danish population‐based study. Journal of the European Academy of Dermatology and Venereology. 39(2). 301–307. 2 indexed citations

Schlesinger, Todd, Leon Kircik, J.Q. Del Rosso, et al.. (2023). Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study). SKIN The Journal of Cutaneous Medicine. 7(3). 771–787. 4 indexed citations

Costanzo, Antonio, Mar Llamas‐Velasco, Gabriella Fabbrocini, et al.. (2023). Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate‐to‐severe plaque psoriasis patients in conditions close to clinical practice. Journal of the European Academy of Dermatology and Venereology. 37(10). 2004–2015. 13 indexed citations

Sommer, Rachel, Ulrich Mrowietz, Kristian Gaarn du Jardin, et al.. (2023). Implementing well‐being in the management of psoriasis: An expert recommendation. Journal of the European Academy of Dermatology and Venereology. 38(2). 302–310. 7 indexed citations

Augustin, Matthias, Rachel Sommer, E. Daudén, et al.. (2023). Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study). BMJ Open. 13(2). e060536–e060536. 8 indexed citations

Kircik, Leon, Todd Schlesinger, April W. Armstrong, et al.. (2023). Impact of Actinic Keratosis (AK), as measured by patient-reported AK symptoms, and impact on emotions and functioning (using Skindex-16) among patients with AK administered tirbanibulin in real-world community practices across the U.S. (PROAK Study). SKIN The Journal of Cutaneous Medicine. 7(2). s161–s161. 1 indexed citations

10.

Schlesinger, Todd, Leon Kircik, April W. Armstrong, et al.. (2023). Investigator Global assessment (IGA) of Actinic Keratosis (AK) among patients administered tirbanibulin in real-world community practices across the U.S., and clinician likelihood to consider tirbanibulin again for future AK treatments (PROAK Study). SKIN The Journal of Cutaneous Medicine. 7(2). s162–s162. 1 indexed citations

11.

Berman, Brian, April W. Armstrong, Mark Lebwohl, et al.. (2023). Developing a questionnaire for assessing clinician- and patient-reported outcomes in actinic keratosis: Results from an expert panel. JAAD International. 16. 192–198.

12.

Kasujee, Ismail, et al.. (2022). Application of the Statistical Method to Convert Published PASI 50/75/90/100 into Absolute PASI Response Rate in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab Based on Data from the Two Pivotal Phase 3 Studies reSURFACE 1 and reSURFACE 2. Dermatology. 238(5). 910–918. 2 indexed citations

13.

Becher, G, et al.. (2022). A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis. Dermatology and Therapy. 12(10). 2343–2354. 14 indexed citations

14.

Bhatia, Neal, April W. Armstrong, Todd Schlesinger, et al.. (2022). An Expert Panel Questionnaire for Assessing Patient-Reported and Clinician-Reported Outcomes in Actinic Keratosis. SKIN The Journal of Cutaneous Medicine. 6(6). s89–s89. 2 indexed citations

15.

Balak, Deepak, Stefano Piaserico, & Ismail Kasujee. (2021). Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies. SHILAP Revista de lepidopterología. Volume 11. 151–168. 27 indexed citations

16.

Κatsaounou, Paraskevi, Mikaëla Odemyr, Michael E. Hyland, et al.. (2018). Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma. ERJ Open Research. 4(4). 76–2018. 27 indexed citations

17.

Matucci, Andrea, Alessandra Vultaggio, Enrico Maggi, & Ismail Kasujee. (2018). Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?. Respiratory Research. 19(1). 113–113. 142 indexed citations

18.

Mansur, Adel, et al.. (2017). Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety. Respiratory Medicine. 124. 36–43. 56 indexed citations

19.

Κatsaounou, Paraskevi, Lorena Garcia Conde, Claus Kroegel, et al.. (2017). Living with severe asthma year 2016. PA4682–PA4682.

20.

Britton, Mark, Timothy R. Howes, Dinesh Saralaya, et al.. (2011). Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 3 UK centres. European Respiratory Journal. 38(Suppl 55). p273–p273. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact